How effective is dupilumab/dalbitux in the treatment of chronic obstructive pulmonary disease?

Dupilumab (dupilumab) is an innovative monoclonal antibody drug targeting interleukin-4 receptor alpha (IL-4Rα). It can simultaneously block the IL-4 and IL-13 signaling pathways, thereby regulating immune responses and inhibiting eosinophilic inflammation. For patients with chronic obstructive pulmonary disease (COPD), particularly those with an eosinophilic phenotype who are poorly controlled with traditional inhaled corticosteroids or bronchodilators, dupilumab offers a novel adjuvant maintenance therapy. Its mechanism of action is to inhibit the release of inflammatory cell mediators and reduce airway mucosal inflammation, thereby reducing the frequency of acute exacerbations and improving patients' respiratory function and quality of life.

Clinical studies have shown that dupilumab can significantly reduce the number of acute exacerbations in patients with COPD and also has potential benefits in maintaining long-term lung function. Compared with traditional treatment, dupilumab places more emphasis on targeted immune regulation and achieves individualized management of the disease by precisely intervening in the eosinophilic inflammation chain. However, it should be noted that dupilumab is not an emergency drug and cannot be used to relieve acute bronchospasm. Its main function is to maintain airway stability and reduce chronic inflammation in the long term.

In clinical practice, patients usually undergo a detailed disease assessment before using dupilumab, including eosinophil level measurement, previous medication history and disease course records, to determine whether they are suitable for this therapy. The emergence of dupilumab marks a shift in the treatment of COPD from traditional bronchiectasis and anti-inflammation to precise immune regulation, providing a new option for high-risk patients. In the future, with the advancement of combination therapy research, this drug may be used in combination with other targeted drugs or immunotherapy to bring more effective treatment options to patients with COPD and related eosinophilic inflammatory diseases.

Reference materials:https://www.drugs.com